Treatment of sialorrhea in Parkinson’s disease
Authors:
- 28 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Movement Disorders
- Vol. 5 (3) , 153-158
Abstract
Sialorrhea is a common disabling nonmotor symptom of Parkinson’s disease. It can lead to several ill effects such as poor orodental hygiene, speech and feeding difficulty, depressive symptoms, poor quality of life, and aspiration pneumonia. It most likely occurs secondary to swallowing dysfunction due to a combination of factors such as lingual bradykinesia, oropharyngeal dysphagia, and esophageal dysmotility, leading to impaired salivary clearance. Various tools are available for its objective assessment to assess drooling in patients with Parkinson’s disease. The treatment options include use of anticholinergic medications and optimization of dopaminergic therapy. However, their use is limited due to the occurrence of adverse effects. Botulinum toxin injections into the parotid and submandibular glands is the most effective and safest treatment available at present.Keywords
This publication has 24 references indexed in Scilit:
- Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12‐Week Controlled TrialMovement Disorders, 2020
- Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in AdultsJAMA Neurology, 2020
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine reviewMovement Disorders, 2019
- Prevalence and definition of drooling in Parkinson’s disease: a systematic reviewJournal of Neurology, 2009
- Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonismMovement Disorders, 2007
- Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's diseaseMovement Disorders, 2007
- Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled studyMovement Disorders, 2006
- Salivary production in Parkinson's diseaseMovement Disorders, 2004
- Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonismMovement Disorders, 2003
- Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot studyMovement Disorders, 2002